VIR Latest Headlines

Barclays Remains a Buy on Vir Biotechnology (VIR)

at www.tipranks.com (Tue, 28-Apr 5:18 AM)

Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target

at www.tipranks.com (Tue, 28-Apr 5:16 AM)

Vir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study Update

at www.tipranks.com (Thu, 23-Apr 12:32 PM)

Vir Biotechnology Sets Sights on March Investor Conferences to Spotlight Its Advancing Pipeline

Market Chameleon (Fri, 27-Feb 8:57 AM)

Vir Biotechnology Launches $200 Million Public Share Offering to Fund Next Phase in Infectious Disease and Oncology Research

Market Chameleon (Wed, 25-Feb 10:37 AM)

Vir Biotechnology Targets $200 Million in New Funding with Public Stock Offering — What Does It Signal for Future Growth?

Market Chameleon (Wed, 25-Feb 7:32 AM)

Strategic Partnerships and Pipeline Progress Strengthen Vir Biotechnology’s Outlook Despite Continued Losses

Market Chameleon (Tue, 24-Feb 9:53 AM)